Access to claims data enables plan sponsors to identify cost drivers, assess the impact of formulary decisions and negotiate ...
The U.S. Food and Drug Administration (FDA) has introduced a new pilot program to prioritize Abbreviated New Drug Applications (ANDAs) for generic drugs that utilize U.S.-based manufacturing and ...
Adam Kautzner will oversee the PCMA’s strategy as chair of the board, including its defense of pharmacy benefit managers amid growing scrutiny of their role in rising drug costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback